Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease

American Journal of Kidney Diseases

Volumn 48, Issue 3, 2006, Pages 341-360

  Roberts, Matthew A ^a   Hare, David L ^a   Ratnaike, Sujiva ^a   Ierino, Francesco L ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

biochemical marker; biomarker; Cardiovascular diseases; chronic kidney failure; diagnosis; dialysis; kidney transplantation; prevention

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMYLOID A PROTEIN; ARGININE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; FETUIN; FIBRINOGEN; HEMOGLOBIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; ISOPROSTANE DERIVATIVE; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NEUROPEPTIDE Y; NITRIC OXIDE; NORADRENALIN; PLASMALOGEN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN; RELAXIN; SELECTIN; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN; VASCULAR CELL ADHESION MOLECULE 1;

ADRENERGIC SYSTEM; ANEMIA; AORTA STENOSIS; ARTERIOSCLEROSIS; ARTERIOVENOUS FISTULA; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALNUTRITION; MICROALBUMINURIA; MINERAL METABOLISM; MORPHOLOGY; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW; RISK FACTOR; SODIUM RETENTION; STATISTICAL SIGNIFICANCE; WATER RETENTION;

BIOLOGICAL MARKERS; BONE MARROW; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; GLYCOSYLATION; HUMANS; INFLAMMATION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MYOCARDIUM; NECROSIS; OXIDATIVE STRESS; PLATELET ACTIVATION; PROTEINS; RISK ASSESSMENT; VENTRICULAR FUNCTION, LEFT;

EID: 33747601865     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000205123.40068.84     Document Type: Review

References (247)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
2. Ruilope L.M., Salvetti A., Jamerson K., et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 12 (2001) 218-225
3. Mann J.F., Gerstein H.C., Pogue J., Bosch J., and Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril. The HOPE randomized trial. Ann Intern Med 134 (2001) 629-636
4. Shlipak M.G., Heidenreich P.A., Noguchi H., Chertow G.M., Browner W.S., and McClellan M.B. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137 (2002) 555-562
5. Anavekar N.S., McMurray J.J.V., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
6. Excell L., and McDonald S. Deaths. In: Excell L., and McDonald S. (Eds). ANZDATA Registry Report 2004 (2004), Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia 15-24
7. Sarnak M.J., Coronado B.E., Greene T., et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57 (2002) 327-335
8. Longenecker J.C., Coresh J., Powe N.R., et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population. The CHOICE Study. J Am Soc Nephrol 13 (2002) 1918-1927
9. Cheung A.K., Sarnak M.J., Yan G., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58 (2000) 353-362
10. Kasiske B.L., Chakkera H.A., and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 (2000) 1735-1743
11. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 suppl 3 (1998) S112-S119
12. Kalantar-Zadeh K., Block G., Humphreys M.H., et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 (2003) 793-808
13. Mogensen C.E., and Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311 (1984) 89-93
14. Hillege H.L., Fidler V., Diercks G.F.H., et al., Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
15. Morrow D.A., de Lemos J.A., Sabatine M.S., and Antman E.M. The search for a biomarker of cardiac ischemia. Clin Chem 49 (2003) 537-539
16. Schulze F., Wesemann R., Schwedhelm E., et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 42 (2004) 1377-1383
17. Valkonen V.P., Paiva H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
18. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
19. Kielstein J.T., Frolich J.C., Haller H., and Fliser D. ADMA (asymmetric dimethylarginine). An atherosclerotic disease mediating agent in patients with renal disease?. Nephrol Dial Transplant 16 (2001) 1742-1745
20. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease. A prospective study. Lancet 358 (2001) 2113-2117
21. Zoccali C., Mallamaci F., Maas R., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62 (2002) 339-345
22. Bennett-Richards K.J., Kattenhorn M., Donald A.E., et al. Oral l-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 62 (2002) 1372-1378
23. Clarkson P., Adams M.R., Powe A.J., et al. Oral l-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 97 (1996) 1989-1994
24. Zoccali C. Asymmetric dimethylarginine (ADMA). A cardiovascular and renal risk factor on the move. J Hypertens 24 (2006) 611-619
25. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
26. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 288 (2002) 2015-2022
27. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
28. Bonaa K.H., Njolstad I., Ueland P.M., et al., NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
29. Hankey G.J., and Eikelboom J.W. Homocysteine and vascular disease. Lancet 354 (1999) 407-413
30. Menon V., Sarnak M.J., Greene T., et al. Relationship between homocysteine and mortality in chronic kidney disease. Circulation 113 (2006) 1572-1577
31. Jungers P., Chauveau P., Bandin O., et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 23 (1997) 170-173
32. Mallamaci F., Zoccali C., Tripepi G., et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61 (2002) 609-614
33. Kalantar-Zadeh K., Block G., Humphreys M.H., McAllister C.J., and Kopple J.D. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 15 (2004) 442-453
34. Ducloux D., Klein A., Kazory A., Devillard N., and Chalopin J.-M. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 69 (2006) 331-335
35. Wrone E.M., Hornberger J.M., Zehnder J.L., McCann L.M., Coplon N.S., and Fortmann S.P. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15 (2004) 420-426
36. Zoungas S., McGrath B.P., Branley P., et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure. A multicenter, randomized, controlled trial. J Am Coll Cardiol 47 (2006) 1108-1116
37. Juskowa J., Bartlomiejczyk J., Paczek L., et al. Total homocysteine as a risk factor for vascular disease in renal transplant recipients. Transplant Proc 34 (2002) 576-579
38. Ducloux D., Kazory A., and Chalopin J.-M. Predicting coronary heart disease in renal transplant recipients. A prospective study. Kidney Int 66 (2004) 441-447
39. Ketteler M., Bongartz P., Westenfeld R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis. A cross-sectional study. Lancet 361 (2003) 827-833
40. Giachelli C.M. Vascular calcification mechanisms. J Am Soc Nephrol 15 (2004) 2959-2964
41. Wang A.Y.-M., Woo J., Lam C.W.-K., et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 20 (2005) 1676-1685
42. Stenvinkel P., Wang K., Qureshi A.R., et al. Low fetuin-A levels are associated with cardiovascular death. Impact of variations in the gene encoding fetuin. Kidney Int 67 (2005) 2383-2392
43. Block G., Hulbert-Shearon T., Levin N., and Port F. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. A national study. Am J Kidney Dis 31 (1998) 607-617
44. Stevens L.A., Djurdjev O., Cardew S., Cameron E.C., and Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality. Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15 (2004) 770-779
45. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 340 (1999) 115-126
46. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
47. Hwang S.-J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96 (1997) 4219-4225
48. Malik I., Danesh J., Whincup P., et al. Soluble adhesion molecules and prediction of coronary heart disease. A prospective study and meta-analysis. Lancet 358 (2001) 971-976
49. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
50. Ridker P.M., Buring J.E., and Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103 (2001) 491-495
51. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
52. Landray M.J., Wheeler D.C., Lip G.Y., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease. The Chronic Renal Impairment in Birmingham (CRIB) Study. Am J Kidney Dis 43 (2004) 244-253
53. Knight E.L., Rimm E.B., Pai J.K., et al. Kidney dysfunction, inflammation, and coronary events. A prospective study. J Am Soc Nephrol 15 (2004) 1897-1903
54. Papayianni A., Alexopoulos E., Giamalis P., et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients. Association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 17 (2002) 435-441
55. Papagianni A., Kalovoulos M., Kirmizis D., et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 18 (2003) 113-119
56. Stenvinkel P., Lindholm B., Heimburger M., and Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients. Association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 15 (2000) 1624-1630
57. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
58. Jialal I., Devaraj S., and Venugopal S.K. C-Reactive protein. Risk marker or mediator in atherothrombosis?. Hypertension 44 (2004) 6-11
59. Arici M., and Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality. Is C-reactive protein the missing link?. Kidney Int 59 (2001) 407-414
60. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
61. Kalantar-Zadeh K., Ikizler T.A., Block G., Avram M.M., and Kopple J.D. Malnutrition-inflammation complex syndrome in dialysis patients. Causes and consequences. Am J Kidney Dis 42 (2003) 864-881
62. Kramer H.J., Saranathan A., Luke A., et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 17 (2006) 1453-1459
63. Hsu C.-Y., McCulloch C.E., Iribarren C., Darbinian J., and Go A.S. Body mass index and risk for end-stage renal disease. Ann Intern Med 144 (2006) 21-28
64. Axelsson J., Rashid Qureshi A., Suliman M.E., et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 80 (2004) 1222-1229
65. van Ree R.M., de Vries A.P.J., Oterdoom L.H., et al. Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant recipients. Nephrol Dial Transplant 20 (2005) 2524-2531
66. Muntner P., Hamm L.L., Kusek J.W., Chen J., Whelton P.K., and He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140 (2004) 9-17
67. Panichi V., Migliori M., and De Pietro S. C-Reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 91 (2002) 594-600
68. Pecoits-Filho R., Heimburger O., Barany P., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41 (2003) 1212-1218
69. Zimmermann J., Herrlinger S., Pruy A., Metzger T., and Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658
70. Menon V., Greene T., Wang X., et al. C-Reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 68 (2005) 766-772
71. Ducloux D., Bresson-Vautrin C., Kribs M., Abdelfatah A., and Chalopin J.M. C-Reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 62 (2002) 1417-1422
72. Iseki K., Tozawa M., Yoshi S., and Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14 (1999) 1956-1960
73. Yeun J.Y., Levine R.A., Mantadilok V., and Kaysen G.A. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35 (2000) 469-476
74. Korevaar J.C., van Manen J.G., Dekker F.W., de Waart D.R., Boeschoten E.W., Krediet R.T., and NECOSAD Study Group. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 15 (2004) 2916-2922
75. Varagunam M., Finney H., Trevitt R., et al. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis 43 (2004) 502-507
76. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
77. Ridker P.M., Rifai N., Clearfield M., et al., Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
78. Vernaglione L., Cristofano C., Muscogiuri P., and Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?. Am J Kidney Dis 43 (2004) 471-478
79. Ikejiri A., Hirano T., Murayama S., et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 53 (2004) 1113-1117
80. Chang J.W., Yang W.S., Min W.K., Lee S.K., Park J.S., and Kim S.B. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39 (2002) 1213-1217
81. Oberg B.P., McMenamin E., Lucas F.L., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65 (2004) 1009-1016
82. Rattazzi M., Puato M., Faggin E., Bertipaglia B., Zambon A., and Pauletto P. C-Reactive protein and interleukin-6 in vascular disease. Culprits or passive bystanders?. J Hypertens 21 (2003) 1787-1803
83. Stenvinkel P., Barany P., Heimburger O., Pecoits-Filho R., and Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD. What is the role of interleukin-6?. Kidney Int Suppl 80 (2002) S103-S108
84. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
85. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
86. St-Pierre A.C., Cantin B., Bergeron J., et al. Inflammatory markers and long-term risk of ischemic heart disease in men. A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 182 (2005) 315-321
87. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
88. Kato A., Odamaki M., Takita T., Maruyama Y., Kumagai H., and Hishida A. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 61 (2002) 1143-1152
89. Shlipak M.G., Fried L.F., Cushman M., et al. Cardiovascular mortality risk in chronic kidney disease. Comparison of traditional and novel risk factors. JAMA 293 (2005) 1737-1745
90. Kimmel P.L., Phillips T.M., Simmens S.J., et al. Immunologic function and survival in hemodialysis patients. Kidney Int 54 (1998) 236-244
91. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32 (1998) 107-114
92. Panichi V., Maggiore U., Taccola D., et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 1154-1160
93. Rao M., Guo D., Perianayagam M.C., et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 45 (2005) 324-333
94. Honda H., Qureshi A.R., Heimburger O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47 (2006) 139-148
95. Barath P., Fishbein M.C., Cao J., Berenson J., Helfant R.H., and Forrester J.S. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 65 (1990) 297-302
96. Blake G.J., and Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ Res 89 (2001) 763-771
97. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
98. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., and Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
99. Bolton C.H., Downs L.G., Victory J.G., et al. Endothelial dysfunction in chronic renal failure. Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16 (2001) 1189-1197
100. Futh R., Herder C., Forster S., et al. Evaluation of diagnostic relevance of mRNA levels in peripheral blood. predictive value for mortality in hemodialysis patients. Cytokine 27 (2004) 166-172
101. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
102. Ernst E., and Koenig W. Fibrinogen and cardiovascular risk. Vasc Med 2 (1997) 115-125
103. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 279 (1998) 1477-1482
104. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 45 (2005) 39-47
105. Enia G., Panuccio V., Mallamaci F., Tripepi G., Mandalari A., and Zoccali C. Fibrinogen and calcium × phosphate product are predictors of cardiovascular events in the CAPD population. J Nephrol 18 (2005) 764-769
106. Zoccali C., Mallamaci F., Tripepi G., et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 254 (2003) 132-139
107. Koch M., Kutkuhn B., Grabensee B., and Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients. A prospective study in 412 subjects. Nephrol Dial Transplant 12 (1997) 2603-2611
108. Tsirpanlis G., Chatzipanagiotou S., Ioannidis A., Moutafis S., Poulopoulou C., and Nicolaou C. Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells. Correlation with inflammation and atherosclerosis in haemodialysis patients. Nephrol Dial Transplant 18 (2003) 918-923
109. Gordon C.A., and Himmelfarb J. Antioxidant therapy in uremia. Evidence-based medicine?. Semin Dial 17 (2004) 327-332
110. Locatelli F., Canaud B., Eckardt K.-U., Stenvinkel P., Wanner C., and Zoccali C. Oxidative stress in end-stage renal disease. An emerging threat to patient outcome. Nephrol Dial Transplant 18 (2003) 1272-1280
111. Dursun E., Dursun B., Suleymanlar G., and Ozben T. Carbonyl stress in chronic renal failure. The effect of haemodialysis. Ann Clin Biochem 42 (2005) 64-66
112. Stenvinkel P., Diczfalusy U., Lindholm B., and Heimburger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant 19 (2004) 972-976
113. Blankenberg S., Rupprecht H.J., Bickel C., et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349 (2003) 1605-1613
114. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P., and Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 154-160
115. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals. A randomised placebo-controlled trial. Lancet 360 (2002) 23-33
116. Mann J.F., Lonn E.M., Yi Q., et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency. Results of the HOPE Study. Kidney Int 65 (2004) 1375-1380
117. Danielski M., Ikizler T.A., McMonagle E., et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 42 (2003) 286-294
118. Boaz M., Smetana S., Weinstein T., et al. Secondary Prevention With Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE). Randomised placebo-controlled trial. Lancet 356 (2000) 1213-1218
119. Tepel M., van der Giet M., Statz M., Jankowski J., and Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. A randomized, controlled trial. Circulation 107 (2003) 992-995
120. Koomans H.A., Blankestijn P.J., and Joles J.A. Sympathetic hyperactivity in chronic renal failure. A wake-up call. J Am Soc Nephrol 15 (2004) 524-537
121. Wallerstedt S.M., Skrtic S., Eriksson A.L., Ohlsson C., and Hedner T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 22 (2004) 1277-1281
122. Zoccali C., Mallamaci F., Tripepi G., et al. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J Hypertens 21 (2003) 1355-1362
123. Zoccali C., Mallamaci F., Tripepi G., et al. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol 14 (2003) 2611-2617
124. Zoccali C., Mallamaci F., Parlongo S., et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105 (2002) 1354-1359
125. Basta G., Schmidt A.M., and De Caterina R. Advanced glycation end products and vascular inflammation. Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63 (2004) 582-592
126. Munch G., Keis R., Wessels A., et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35 (1997) 669-677
127. Wrobel K., Garay-Sevilla M.E., Nava L.E., and Malacara J.M. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 43 (1997) 1563-1569
128. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
129. Thomas M., Tsalamandris C., MacIsaac R., et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 66 (2004) 1167-1172
130. Busch M., Franke S., Muller A., et al. Potential cardiovascular risk factors in chronic kidney disease. AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 66 (2004) 338-347
131. Suliman M.E., Heimburger O., Barany P., et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 14 (2003) 1614-1622
132. Schwedler S.B., Metzger T., Schinzel R., and Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62 (2002) 301-310
133. Roberts M.A., Thomas M.C., Fernando D., Macmillan N., Power D.A., and Ierino F.L. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 21 (2006) 1611-1617
134. Wagner Z., Molnar M., Molnar G.A., et al. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 47 (2006) 294-300
135. Uribarri J., Peppa M., Cai W., et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14 (2003) 728-731
136. Hammes H.P., Du X., Edelstein D., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9 (2003) 294-299
137. Miyata T., van Ypersele de Strihou C., Ueda Y., et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products. Biochemical mechanisms. J Am Soc Nephrol 13 (2002) 2478-2487
138. Forbes J.M., Yee L.T., Thallas V., et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53 (2004) 1813-1823
139. Candido R., Forbes J.M., Thomas M.C., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92 (2003) 785-792
140. Herrmann K.L., McCulloch A.D., and Omens J.H. Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 284 (2003) H1277-H1284
141. Marsden J.T. Erythropoietin-Measurement and clinical applications. Ann Clin Biochem 43 (2006) 97-104
142. Robinson B.M., Joffe M.M., Berns J.S., Pisoni R.L., Port F.K., and Feldman H.I. Anemia and mortality in hemodialysis patients. Accounting for morbidity and treatment variables updated over time. Kidney Int 68 (2005) 2323-2330
143. Zhang Y., Thamer M., Stefanik K., Kaufman J., and Cotter D.J. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
144. Levin A., Djurdjev O., Thompson C., et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46 (2005) 799-811
145. Parfrey P.S., Foley R.N., Wittreich B.H., Sullivan D.J., Zagari M.J., Frei D., and Canadian European Study. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
146. Strippoli G.F.M., Craig J.C., Manno C., and Schena F.P. Hemoglobin targets for the anemia of chronic kidney disease. A meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15 (2004) 3154-3165
147. Rafii S., and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9 (2003) 702-712
148. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
149. de Groot K., Hermann Bahlmann F., Sowa J., et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 66 (2004) 641-646
150. Choi J.H., Kim K.L., Huh W., et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24 (2004) 1246-1252
151. Herbrig K., Pistrosch F., Oelschlaegel U., et al. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 44 (2004) 840-849
152. Soler M.J., Martinez-Estrada O.M., Puig-Mari J.M., et al. Circulating endothelial progenitor cells after kidney transplantation. Am J Transplant 5 (2005) 2154-2159
153. de Groot K., Bahlmann F.H., Bahlmann E., Menne J., Haller H., and Fliser D. Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation 79 (2005) 941-945
154. Steiner S., Winkelmayer W.C., Kleinert J., et al. Endothelial progenitor cells in kidney transplant recipients. Transplantation 81 (2006) 599-606
155. Prasad K.S., Andre P., Yan Y., and Phillips D.R. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 10 (2003) 356-361
156. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
157. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
158. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L. Risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
159. Schwabe R.F., Engelmann H., Hess S., and Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol 117 (1999) 153-158
160. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
161. Cipollone F., Mezzetti A., Porreca E., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effects of statin therapy. Circulation 106 (2002) 399-402
162. Malyszko J., Malyszko J.S., Hryszko T., and Mysliwiec M. Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagul Fibrinolysis 15 (2004) 463-467
163. Graff J., Harder S., Wahl O., Scheuermann E.-H., and Gossmann J. Anti-inflammatory effects of clopidogrel intake in renal transplant patients. Effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Ther 78 (2005) 468-476
164. Stein B.C., and Levin R.I. Natriuretic peptides. Physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 135 (1998) 914-923
165. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides. The endocrine heart revisited. Clin Chem 50 (2004) 1503-1510
166. McCullough P.A., Omland T., and Maisel A.S. B-Type natriuretic peptides. A diagnostic breakthrough for clinicians. Rev Cardiovasc Med 4 (2003) 72-80
167. Panteghini M., and Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide. The prerequisite for its optimal clinical use. Clin Lab 50 (2004) 325-331
168. deFilippi C.R., Fink J.C., Nass C.M., Chen H., and Christenson R. N-Terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 46 (2005) 35-44
169. Vickery S., Price C.P., John R.I., et al. B-Type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD. Relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46 (2005) 610-620
170. Tsutamoto T., Wada A., Sakai H., et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 47 (2006) 582-586
171. McCullough P.A., and Sandberg K.R. B-Type natriuretic peptide and renal disease. Heart Fail Rev 8 (2003) 355-358
172. Richards M., Nicholls M.G., Espiner E.A., et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 47 (2006) 52-60
173. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
174. Omland T., Persson A., Ng L., et al. N-Terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
175. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
176. Takami Y., Horio T., Iwashima Y., et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 44 (2004) 420-428
177. Nishikimi T., Futoo Y., Tamano K., et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients. Influence of coronary artery disease. Am J Kidney Dis 37 (2001) 1201-1208
178. Naganuma T., Sugimura K., Wada S., et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22 (2002) 437-444
179. Osajima A., Okazaki M., Kato H., et al. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol 21 (2001) 112-119
180. Nakatani T., Naganuma T., Masuda C., Uchida J., Sugimura T., and Sugimura K. Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis. Int J Mol Med 10 (2002) 457-461
181. Mallamaci F., Zoccali C., Tripepi G., et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59 (2001) 1559-1566
182. Cataliotti A., Malatino L.S., Jougasaki M., et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease. Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 76 (2001) 1111-1119
183. Carr S.J., Bavanandan S., Fentum B., and Ng L. Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients. Clin Sci (Lond) 109 (2005) 75-82
184. Anwaruddin S., Lloyd-Jones D.M., Baggish A., et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement. Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47 (2006) 91-97
185. Zoccali C., Mallamaci F., Benedetto F.A., et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12 (2001) 1508-1515
186. Apple F.S., and Wu A.H. Myocardial infarction redefined. Role of cardiac troponin testing. Clin Chem 47 (2001) 377-379
187. Freda B.J., Tang W.H., Van Lente F., Peacock W.F., and Francis G.S. Cardiac troponins in renal insufficiency. Review and clinical implications. J Am Coll Cardiol 40 (2002) 2065-2071
188. Heidenreich P.A., Alloggiamento T., Melsop K., McDonald K.M., Go A.S., and Hlatky M.A. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes. A meta-analysis. J Am Coll Cardiol 38 (2001) 478-485
189. Olatidoye A.G., Wu A.H., Feng Y.J., and Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 81 (1998) 1405-1410
190. Heeschen C., Hamm C.W., Goldmann B., Deu A., Langenbrink L., White H.D., and PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 354 (1999) 1757-1762
191. Hamm C.W., Heeschen C., Goldmann B., et al., c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 340 (1999) 1623-1629
192. Newby L.K., Ohman E.M., Christenson R.H., et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B Troponin T Substudy. Circulation 103 (2001) 2891-2896
193. Sabatine M.S., and Antman E.M. The Thrombolysis in Myocardial Infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 41 suppl S (2003) 89S-95S
194. Abbas N.A., John R.I., Webb M.C., et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 51 (2005) 2059-2066
195. Apple F.S., Murakami M.M., Pearce L.A., and Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106 (2002) 2941-2945
196. Goicoechea M., Garca de Vinuesa S., Gomez-Campdera F., et al. Clinical significance of cardiac troponin T levels in chronic kidney disease patients. Predictive value for cardiovascular risk. Am J Kidney Dis 43 (2004) 846-853
197. Wood G.N., Keevil B., Gupta J., et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease. A 2 year prospective study. Nephrol Dial Transplant 18 (2003) 1610-1615
198. Iliou M.C., Fumeron C., Benoit M.O., et al. Prognostic value of cardiac markers in ESRD. Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) Study. Am J Kidney Dis 42 (2003) 513-523
199. Dierkes J., Domrose U., Westphal S., et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102 (2000) 1964-1969
200. Ishii J., Nomura M., Okuma T., et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 312 (2001) 69-79
201. Mallamaci F., Zoccali C., Parlongo S., et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 40 (2002) 68-75
202. Ooi D.S., Zimmerman D., Graham J., and Wells G.A. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 47 (2001) 412-417
203. Duman D., Tokay S., Toprak A., Duman D., Oktay A., and Ozener I.C. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 20 (2005) 962-967
204. Lowbeer C., Gutierrez A., Gustafsson S.A., Norrman R., Hulting J., and Seeberger A. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. Nephrol Dial Transplant 17 (2002) 2178-2183
205. Boulier A., Jaussent I., Terrier N., et al. Measurement of circulating troponin Ic enhances the prognostic value of C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 2313-2318
206. Beciani M., Tedesco A., Violante A., et al. Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients. Prevalence and prognostic value. Nephrol Dial Transplant 18 (2003) 942-946
207. Roberts M.A., Fernando D., Macmillan N., et al. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. Clin Nephrol 61 (2004) 40-46
208. Khan N.A., Hemmelgarn B.R., Tonelli M., Thompson C.R., and Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease. A meta-analysis. Circulation 112 (2005) 3088-3096
209. Chapelle J.P., Dubois B., Bovy C., Aldenhoff M.C., Gielen J., and Rorive G. Comparison of plasma cardiac troponins T and I in chronically hemodialyzed patients in relation to cardiac status and age. Clin Chem Lab Med 40 (2002) 240-245
210. Fehr T., Knoflach A., Ammann P., Pei P., and Binswanger U. Differential use of cardiac troponin T versus I in hemodialysis patients. Clin Nephrol 59 (2003) 35-39
211. Iliou M.C., Fumeron C., Benoit M.O., et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients. Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study. Nephrol Dial Transplant 16 (2001) 1452-1458
212. Li D., Jialal I., and Keffer J. Greater frequency of increased cardiac troponin T than increased cardiac troponin I in patients with chronic renal failure. Clin Chem 42 (1996) 114-115
213. Musso P., Cox I., Vidano E., Zambon D., and Panteghini M. Cardiac troponin elevations in chronic renal failure. Prevalence and clinical significance. Clin Biochem 32 (1999) 125-130
214. Roppolo L.P., Fitzgerald R., Dillow J., Ziegler T., Rice M., and Maisel A. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital. A pilot study. J Am Coll Cardiol 34 (1999) 448-454
215. Ooi D.S., and House A.A. Cardiac troponin T in hemodialyzed patients. Clin Chem 44 (1998) 1410-1416
216. Tarakcioglu M., Erbagci A., Cekmen M., et al. Acute effect of haemodialysis on serum markers of myocardial damage. Int J Clin Pract 56 (2002) 328-332
217. Wayand D., Baum H., Schatzle G., Scharf J., and Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem 46 (2000) 1345-1350
218. Willging S., Keller F., and Steinbach G. Specificity of cardiac troponins I and T in renal disease. Clin Chem Lab Med 36 (1998) 87-92
219. Mockel M., Schindler R., Knorr L., et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes. A 9-month outcome analysis. Nephrol Dial Transplant 14 (1999) 1489-1495
220. Lowbeer C., Stenvinkel P., Pecoits-Filho R., et al. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. J Intern Med 253 (2003) 153-160
221. Farkouh M.E., Robbins M.J., Urooj Zafar M., et al. Association between troponin I levels and mortality in stable hemodialysis patients. Am J Med 114 (2003) 224-226
222. Tun A., Khan I.A., Win M.T., et al. Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers. Cardiology 90 (1998) 280-285
223. Wu A.H., Feng Y.J., Roper L., Herbert K., and Schweizer R. Cardiac troponins T and I before and after renal transplantation. Clin Chem 43 (1997) 411-412
224. McNeil A.R. Implications of a rapid decrease in serum troponin T levels after renal transplantation. Aust N Z J Med 30 (2000) 638-639
225. Ellis K., Dreisbach A.W., and Lertora J.L. Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 94 (2001) 993-996
226. Ziebig R., Lun A., Hocher B., et al. Renal elimination of troponin T and troponin I. Clin Chem 49 (2003) 1191-1193
227. Diris J.H., Hackeng C.M., Kooman J.P., Pinto Y.M., Hermens W.T., and van Dieijen-Visser M.P. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation 109 (2004) 23-25
228. Fahie-Wilson M.N., Carmichael D.J., Delaney M.P., Stevens P.E., Hall E.M., and Lamb E.J. Cardiac troponin T circulates in the free, intact form in patients with kidney failure. Clin Chem 52 (2006) 414-420
229. Fernandez-Reyes M.J., Mon C., Heras M., et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. J Nephrol 17 (2004) 721-727
230. Mallamaci F., Zoccali C., Parlongo S., et al. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int 62 (2002) 1884-1890
231. deFilippi C.R., Tocchi M., Parmar R.J., et al. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes. Angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol 35 (2000) 1827-1834
232. Lauer M.S. Cardiac troponins and renal failure. The evolution of a clinical test. Circulation 112 (2005) 3036-3037
233. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
234. Hocher B., Ziebig R., Krause R., et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation 109 (2004) 2266-2268
235. Panichi V., Taccola D., Rizza G.M., et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract 102 (2006) c51-c58
236. Kalousova M., Horejsi M., Fialova L., et al. Increased levels of pregnancy-associated plasma protein A are associated with mortality in hemodialysis patients. Preliminary results. Blood Purif 22 (2004) 298-300
237. Lauzurica R., Pastor C., Bayes B., Hernandez J.M., and Romero R. Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events. Transplantation 80 (2005) 1441-1446
238. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
239. James S.K., Lindahl B., Siegbahn A., et al. N-Terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A Global Utilization of Strategies To Open Occluded Arteries (GUSTO)-IV Substudy. Circulation 108 (2003) 275-281
240. deFilippi C., Wasserman S., Rosanio S., et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290 (2003) 353-359
241. Apple F.S., Murakami M.M., Pearce L.A., and Herzog C.A. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 50 (2004) 2279-2285
242. Mallamaci F., Tripepi G., Cutrupi S., Malatino L.S., and Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 67 (2005) 2330-2337
243. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
244. Li S., Foley R.N., and Collins A.J. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 65 (2004) 1864-1869
245. Rigatto C., Parfrey P., Foley R., Negrijn C., Tribula C., and Jeffery J. Congestive heart failure in renal transplant recipients. Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 13 (2002) 1084-1090
246. Panichi V., Paoletti S., Mantuano E., et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 21 (2006) 337-344
247. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. A prospective, placebo-controlled trial. J Am Coll Cardiol 41 (2003) 1438-1444